Gut Microbes: Regulating uric acid
Certain strains of a bacterium found in the gut of some animals, Lactobacillus plantarum, are able to counter hyperuricemia, a condition caused by high levels of uric acid in the blood.
- College of Animal Sciences, Zhejiang University, China
Improvements in the quality of life have led to an increase in the incidence of hyperuricemia, a medical condition that can lead to kidney stones and gout, with cases increasingly affecting younger individuals (Johnson et al., 2018; Zhang et al., 2019). Hyperuricemia – the presence of abnormally high levels of uric acid in the blood – arises from interactions between the liver, the kidneys and the gut, which has a role in removing uric acid from the body (Dalbeth et al., 2021; Niu et al., 2018; Yun et al., 2017). Studies indicate that gut microbes are crucial to uric acid metabolism, and interventions such as probiotics, prebiotics and fecal microbiota transplants can help reduce hyperuricemia by altering the gut microbiota (Cao et al., 2022a; Wang et al., 2022; Zhao et al., 2022).
It has been shown that various strains of bacteria can alleviate hyperuricemia through two mechanisms: the direct hydrolysis of uric acid, and the hydrolase-mediated degradation of nucleosides that are the precursors of uric acid in the intestine. Limosilactobacillus fermentum JL-3 – a strain isolated from Chinese mud water – is capable of the hydrolysis of uric acid (Wu et al., 2021), whereas various strains of Lactobacillus, a well-known genus of bacteria, reduce uric acid levels through the hydrolysis of nucleosides in the intestine: these strains include L. paracasei (X11; Cao et al., 2022b) and strains of L. plantarum derived from Chinese sauerkraut (DM9218-A; Li et al., 2014) and Chinese mustard (GKM3; Hsu et al., 2019).
Recent studies have revealed that gene cloning can be used to identify specific hydrolases involved in the degradation of nucleosides for L. plantarum and L. aviarius (Li et al., 2023b; Li et al., 2023a). However, the precise mechanisms underlying the hydrolysis of the nucleoside precursors of uric acid have remained unclear. Now, in eLife, Wence Wang (South China Agricultural University), Qiang Tu (Shandong University) and colleagues – including Yang Fu as first author – report the results of in vitro studies and experiments on geese and mice that shed new light on the hydrolysis of these precursors (Fu et al., 2024).
The team isolated a strain called L. plantarum SQ001 from geese with hyperuricemia, and a genome-wide analysis revealed the presence of four genes that code for nucleoside hydrolysis-related enzymes (iunH, yxjA, rihA, rihC). In vitro experiments revealed that one of these enzymes, iunH, effectively catalyzes the hydrolysis of nucleosides, such as inosine and guanosine, converting them to nucleobases, as evidenced by metabolomics analysis. The hydrolysis mechanism was further validated through experiments that involved knocking out the gene for iunH in L. plantarum SQ001, and expressing it in E. coli. Although nucleosides are hydrolyzed to produce nucleobases, the direct link between this process and the reduction of uric acid remains unclear, possibly due to the transport of nucleosides and nucleobases in the gut. It may be that the lower uptake of these substances reduces the synthesis and accumulation of uric acid.
The team validated the functionality of L. plantarum SQ001 by establishing models of hyperuricemia in both geese and mice (Figure 1), and showed that this particular strain significantly enhanced the abundance of Lactobacillus in the gut of the host, which alleviated the symptoms of hyperuricemia by reducing the synthesis of uric acid and increasing its excretion. The fact that hyperuricemia was alleviated in mice may help with efforts to develop new ways to treat hyperuricemia and gout in humans.
Figure 1
Lactobacillus plantarum reduces uric acid synthesis through the hydrolysis of nucleosides.
A strain of the bacterium L. plantarum was isolated from the large intestine of geese with hyperuricemia, a condition caused by the presence of abnormally high levels of uric acid in the blood (top left). In vitro experiments showed that the presence of the bacteria led to an increase in the degradation of nucleosides that are precursors of uric acid. Administering the bacteria to healthy geese and mice (top right) also led to a reduction in the levels of uric acid in the blood. Other experiments showed that L. plantarum absorbed the nucleosides, and that an enzyme called iunH broke down the nucleosides to produce nucleobases (bottom).
Figure created with figdraw.com.
References
-
Lactobacillus paracasei X11 ameliorates hyperuricemia and modulates gut microbiota in miceFrontiers in Immunology 13:940228.https://doi.org/10.3389/fimmu.2022.940228
-
Antiobesity and uric acid-lowering effect of Lactobacillus plantarum GKM3 in high-fat-diet-induced obese ratsJournal of the American College of Nutrition 38:623–632.https://doi.org/10.1080/07315724.2019.1571454
-
Inhibition of 3,5,2’,4’-tetrahydroxychalcone on production of uric acid in hypoxanthine-induced hyperuricemic miceBiological & Pharmaceutical Bulletin 41:99–105.https://doi.org/10.1248/bpb.b17-00655
-
The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategiesCritical Reviews in Food Science and Nutrition 62:3979–3989.https://doi.org/10.1080/10408398.2021.1874287
-
Hyperuricemia and cardiovascular diseaseCurrent Pharmaceutical Design 25:700–709.https://doi.org/10.2174/1381612825666190408122557
-
The potential of probiotics in the amelioration of hyperuricemiaFood & Function 13:2394–2414.https://doi.org/10.1039/D1FO03206B
Article and author information
Author details
Publication history
Copyright
© 2024, Hu
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 212
- views
-
- 18
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Gut Microbes: Regulating uric acid
eLife 13:e104493.
https://doi.org/10.7554/eLife.104493
Further reading
-
- Cell Biology
- Microbiology and Infectious Disease
Zika virus (ZIKV) infection causes significant human disease that, with no approved treatment or vaccine, constitutes a major public health concern. Its life cycle entirely relies on the cytoplasmic fate of the viral RNA genome (vRNA) through a fine-tuned equilibrium between vRNA translation, replication, and packaging into new virions, all within virus-induced replication organelles (vROs). In this study, with an RNA interference (RNAi) mini-screening and subsequent functional characterization, we have identified insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) as a new host dependency factor that regulates vRNA synthesis. In infected cells, IGF2BP2 associates with viral NS5 polymerase and redistributes to the perinuclear viral replication compartment. Combined fluorescence in situ hybridization-based confocal imaging, in vitro binding assays, and immunoprecipitation coupled to RT-qPCR showed that IGF2BP2 directly interacts with ZIKV vRNA 3’ nontranslated region. Using ZIKV sub-genomic replicons and a replication-independent vRO induction system, we demonstrated that IGF2BP2 knockdown impairs de novo vRO biogenesis and, consistently, vRNA synthesis. Finally, the analysis of immunopurified IGF2BP2 complex using quantitative mass spectrometry and RT-qPCR revealed that ZIKV infection alters the protein and RNA interactomes of IGF2BP2. Altogether, our data support that ZIKV hijacks and remodels the IGF2BP2 ribonucleoprotein complex to regulate vRO biogenesis and vRNA neosynthesis.
-
- Genetics and Genomics
- Microbiology and Infectious Disease
The sustained success of Mycobacterium tuberculosis as a pathogen arises from its ability to persist within macrophages for extended periods and its limited responsiveness to antibiotics. Furthermore, the high incidence of resistance to the few available antituberculosis drugs is a significant concern, especially since the driving forces of the emergence of drug resistance are not clear. Drug-resistant strains of Mycobacterium tuberculosis can emerge through de novo mutations, however, mycobacterial mutation rates are low. To unravel the effects of antibiotic pressure on genome stability, we determined the genetic variability, phenotypic tolerance, DNA repair system activation, and dNTP pool upon treatment with current antibiotics using Mycobacterium smegmatis. Whole-genome sequencing revealed no significant increase in mutation rates after prolonged exposure to first-line antibiotics. However, the phenotypic fluctuation assay indicated rapid adaptation to antibiotics mediated by non-genetic factors. The upregulation of DNA repair genes, measured using qPCR, suggests that genomic integrity may be maintained through the activation of specific DNA repair pathways. Our results, indicating that antibiotic exposure does not result in de novo adaptive mutagenesis under laboratory conditions, do not lend support to the model suggesting antibiotic resistance development through drug pressure-induced microevolution.
